Synthesis and biological evaluation of new 4β-5-Fu-substituted 4′-demethylepipodophyllotoxin derivatives

Molecules

Volumn 11, Issue 11, 2006, Pages 849-857

  Zhang, Fu Min ^a   Yao, Xiao Jun ^a   Tian, Xuan ^a,b   Tu, Yong Qiang ^a  

^a LANZHOU UNIVERSITY   (China)

^b Xinjiang Prod and Constr Corps Key Lab of Protect and Utiliz of Biol Resources in Tarim Basin   (China)

Author keywords

4 Demethylepipodophyllotoxin; 5 fluorouracil; Anticancer activities; Partition coefficients

Indexed keywords

ANTINEOPLASTIC AGENT; DRUG DERIVATIVE; FLUOROURACIL; PODOPHYLLOTOXIN;

ANIMAL; ARTICLE; CELL DEATH; CHEMISTRY; DRUG DESIGN; DRUG EFFECT; DRUG SCREENING; HUMAN; IC 50; MOUSE; STRUCTURE ACTIVITY RELATION; SYNTHESIS; TUMOR CELL LINE;

ANIMALS; ANTINEOPLASTIC AGENTS; CELL DEATH; CELL LINE, TUMOR; DRUG DESIGN; DRUG SCREENING ASSAYS, ANTITUMOR; FLUOROURACIL; HUMANS; INHIBITORY CONCENTRATION 50; MICE; PODOPHYLLOTOXIN; STRUCTURE-ACTIVITY RELATIONSHIP;

EID: 33845401015     PISSN: 14203049     EISSN: 14203049     Source Type: Journal    
DOI: 10.3390/11110849     Document Type: Article

References (37)

1. Canel, C.; Moraes, R. M.; Dayan, F. E.; Ferreira, D. Molecules of interest: podophyllotoxin. Phytochemistry 2000, 54, 115-120.
2. Gordaliza, M.; García, P. A.; Miguel del Corral, J. M.; Castro, M. A.; Gómez-Zurita, M. A. Podophyllotoxin: distribution, sources, applications and new cytotoxic derivatives. Toxicon 2004, 44, 441-459.
3. Hande, K. R. Etoposide: four decades of development of a topoisomerase II Inhibitor. Eur. J. Cancer 1998, 34, 1514-1521.
4. Lee, K. H. Molecular modification of lead compound to develop potent antitumor and anti-HIV agents. UNESCO Regional Symposium on the Chemistry of Medicinal Plants; March 17-19, 2000, Kunming, China, pp. 14-26.
5. Dantzig, A.; LaLoude, R. T.; Ramdayal, F.; Shepard, R.L.; Yanai, K.; Zhang, M. Cytotoxic responses to aromatic ring and configurational variations in α-conidendrin, podophyllotoxin and sikkimotoxin derivatives. J. Med. Chem. 2001, 44, 180-185.
6. Gordaliza, M.; Miguel del Corral, J. M.; Castro, M. A.; García-García, P. A.; Feliciano, A. S. Cytotoxic cyclolignans related to podophyllotoxin. Farmaco 2001, 56, 297-304.
7. Roulland, E.; Magiatis, P.; Arimondo, P.; Bertounesque, E.; Monneret, C. Hemi-synthesis and biological activity of new analogues of podophyllotoxin. Bioorg. Med. Chem. 2002, 10, 3463-3471.
8. Kamal, A.; Gayatri, N. L.; Reddy, D. R.; Reddy, P. S. M. M.; Arifuddin, M.; Dastidar, S. G.; Kondapi, A. K.; Rajkumar, M. Synthesis and biological evalution of new 4β-anilino- and 4β-imido-substituted podophyllotoxin congeners. Bioorg. Med. Chem. 2005, 13, 6218-6225.
9. Castro, M. A.; Miguel del Corral, J. M.; Gordaliza, M.; García, P. A.; Gómez-Zurita, M. A.; García-Grávalos, M. D.; de la Iglesia-Vicente, J.; Gajate, C.; An, F.; Mollinedo, F.; San Feliciano, A. Synthesis and biological evaluation of new selective cytotoxic cyclolignans derived from podophyllotoxin. J. Med. Chem. 2004, 47, 1214-1222.
10. Guianvarc'h, D.; Duca, M.; Boukarim, C.; Kraus-Berthier, L.; Léonce, S.; Pierré, A.; Pfeiffer, B.; Renard, P.; Arimondo, P. B.; Monneret, C.; Dauzonne, D. Synthesis and biological activity of sulfonamide derivatives of epipodophyllotoxin. J. Med. Chem. 2004, 47, 2365-2374.
11. Saladino, R.; Fiani, C.; Belfiore, M. C.; Gualandi, G.; Penna, S.; Mosesso, P. Methyltrioxorhenium catalysed synthesis of highly oxidised aryltetralin lignans with anti-topoisomerase II and apoptogenic activities. Bioorg. Med. Chem. 2005, 13, 5949-5960.
12. Imbert T. F. Discovery of podophyllotoxins. Biochimie 1998, 80, 207-222.
13. Srivastava, V.; Negi, A. S.; Kumar, J. K.; Gupta, M. M.; Khanuja, S. P. S. Plant-based anticancer molecules: a chemical and biological profile of some important leads. Bioorg. Med. Chem. 2005, 13, 5892-5908.
14. Cragg, G. M.; Newman, D. J. Plants as a source of anti-cancer agents. J. Ethnopharmacol. 2005, 100, 72-79.
15. Heidelberger, C.; Chaudhuri, N. K.; Danneberg, P.; Mooren, D.; Griesbach, L. Fluorinated pyrimidines, a new class of tumor-inhibitory compounds. Nature 1957, 179, 663-666.
16. Cunningham, D.; James, R. D. Integrating the oral fluoropyrimidines into the management of advanced colorectal cancer. Eur. J. Cancer 2001, 37, 826-834.
17. Ozaki, S.; Watanabe, Y.; Hoshiko, T.; Mizuno, H.; Ishikawa, K.; Mori, H. 5-Fluorouracil derivatives (IV): Synthesis of antitumor active acyloxyalkyl-5-fluouracils. Chem. Pharm. Bull. 1984, 32, 733-738.
18. McElhinney, R. S.; McCormick, J. E.; Bibby, M. C.; Double, J. A.; Radacic, M.; Dumont, P. Nucleoside Analogs. 14. The synthesis and antitumor activity in mice of molecular combinations of 5-fluorouracil and N- (2-chloroethyl)-N-nitrosourea moieties separated by a three-carbon chain. J. Med. Chem. 1996, 39, 1403-1412.
19. Mori, M.; Hatta, H.; Nishimoto, S. Stereoelectronic effect on one-electron reductive release of 5-fluorouracil from 5-fluoro-1-(2′- oxocycloalky)uracils as a new class of radiation-activated antitumor prodrugs. J. Org. Chem. 2000, 65, 4641-4647.
20. Bill-Cai, T.; Tang, X.; Nagorski, J.; Brauschweiger, P. G.; Wang, P. G. Synthesis and cytotoxicity of 5-fluorouracil/diazeniumdiolate conjugates. Bioorg. Med. Chem. 2003, 11, 4971-4975.
21. Domínguez, J. F.; Marchal, J. A.; Correa, A.; Carrillo, E.; Boulaiz, H.; Aránega, A.; Gallo, M. A.; Espinosa, A. Synthesis and evaluation of new 5-fluorouracil antitumor cell differentiating derivatives. Bioorg. Med. Chem. 2003, 11, 315-323.
22. Díaz-Gavilán, M.; Gómez-Vidal, J. A.; Entrena, A.; Gallo, M. A.; Espinosa, A.; Campos, J. M. Study of the factors that control the ratio of the products between 5-fluorouracil, uracil, and tetrahydrobenzoxazepine O,O-acetals bearing electron-withdrawing groups on the nitrogen atom. J. Org. Chem. 2006, 71, 1043-1054.
23. Tian, X.; Wang, Y. G.; Yang, M. G.; Chen, Y. Z. Synthesis and antitumor activity of spin labeled derivatives of podophyllotoxin. Life Sci. 1997, 60, 511-517.
24. Cui, Y. J.; Tian, X. Synthesis and anticancer activity of new derivatives of podophyllotoxin. Curr. Sci. 1998, 75, 1383-1386.
25. Tian, X.; Zhang, F. M.; Li, W. G. Antitumor and antioxidant activity of spin labeled derivatives of podophyllotoxin (GP-1) and congeners. Life Sci. 2002, 70, 2433-2443.
26. Zhang, F. M.; Tian, X. Synthesis and anticancer activity of novel derivatives of 4′-demethylepipodophyllotoxin. Acta Chim. Sinica 2002, 60, 720-724.
27. Chen, S. W.; Tian, X.; Tu, Y. Q. Synthesis and cytotoxic activity of novel derivatives of 4′-demethylepipodophyllotoxin. Bioorg. Med. Chem. Lett. 2004, 14, 5063-5066.
28. Jin, Y.; Chen, S. W.; Tian, X. Synthesis and biological evalution of new spin-labled derivatives of podophyllotoxin. Bioorg. Med. Chem. 2006, 14, 3062-3068.
29. Wang, J.Z.; Tian, X.; Tsumura, H.; Shimura, K.; Ito, H. Antitumor activity of a new low immunosuppressive derivative of podophyllotoxin (GP-11) and its mechanisms. Anti-cancer Drug Des. 1993, 8, 193-202.
30. Marx, J. L. Drug resistance of cancer cells probed. Science 1986, 234, 818-820.
31. Hofffmann, M.; Chrzanowska, M.; Hermann, T.; Rychlewski, J. Modeling of purine derivatives transport across cell membranes based on their partition coefficient determination and quantum chemical calculations. J. Med. Chem. 2005, 48, 4482-4486.
32. Zhang, H. A new approach for the tissue-blood partition coefficients of neutral and ionized compounds. J. Chem. Inf. Model. 2005, 45, 121-127.
33. Sosnovsky, G. The quest for a predictive design of anticancer drugs. Pure Appl. Chem. 1990, 62, 289-294.
34. Sosnovsky, G.; Bell, P. In the search for new anticancer drugs. 29. A study on the correlation of lipophilicities, ionization constants and anticancer activities of aminoxyl labeled TEPA congeners. Life Sci. 1998, 62, 639-647.
35. Mosmann, T. Rapid colorimetric assay for cellular growth and survival: application to proliferation and cytotoxicity assays. J. Immunol. Meth. 1983, 65, 55-63.
36. Skeham, P.; Storeng, R.; Scudiero D.; Monks, A.; McMahon, J.; Vistica, D.; Warren, J. T.; Bokesch, H.; Kenney, S.; Boyd, M. R. New colorimetric cytotoxic assay for anticancer drug screening. J. Natl. Cancer Inst. 1990, 82, 1107-1112
37. Purcell, W. P.; Bass, G. E.; Clayton, J. M. Strategy of Drug Design: A Guide to Biological Activity; Wiley: New York, 1973; pp. 131-133.